"with a full FDA lift"
If you're talking about 1625, it's really not all that important ... they have 2684 which is Gen 2 PI and far better than 1625 ... they also have 3102 which is a me-too NS5A ... the jewel in the crown is 3422 NS5B nuke ... which will be the clincher ...
Ur handles appropriate u should be very very nervous :))
Hey nervous man. Perhaps u don't know but Achn buyout rumors were reported in the mainstream media at the time of the Idix buyout. There's nothing new in this story.
ACHN is worth at least as much as IDIX for its nuke (3422) which is $3.8 billion, add another 1.2 billion for 2684/ sovaprevir/ 3102 makes it worth $5 billion ... a lot more than IDIX went for ...
Ok thanks ... can I ask you a question ... what are the topics he gave you more specifics on -- (a) when the buy-out would happen, (b) how many parties are interested, (c) any indication of the buy-out price ... is it a, b, and/or c ?
The other 15.3 million short positions are scrambling to cover ... as they run for the exits, they will get trampled ...
Per Nasdaq site --
ACHN short interest
Between 6/13 and 6/30, there was a DECREASE of 6.59 million in short interest.
"Don't know exactly whether they want to wait for both trial duration or release one Data Set at a time."
They will release the 8 week trial results first ...
ACHN has said at various investor conferences that they expect to release the results of the 3102/sofosbuvir 8 week trial in summer, and the 3422 P1 POC trial in early fall.
I personally expect before Aug 11 for the former and before Nov 10 for the latter.
" when its counterpart was just bought out for 3 times what it trades at"
Correction -- ACHN market cap at 7.50 pps is $730 million ... IDIX buy-out price was $3.85 billion!
The ratio of market caps is 5.3!
ACHN is trading at 5.3 times lower than IDIX buyout, or in other words it is trading at 19% of the IDIX buyout price ...
That kinda talk has been around for a long time ... is there something in particular your friend said that's new?
The 3102/sofosbuvir 8 week trial results are due out soon ... we should see a PR on the SVR12 and the SVR4 ... shorts have not covered yet ... lot more covering to come ... expect a short squeeze ... anyone have any ideas on how high the next piece of news takes the pps without a short squeeze ... then you can add another 15% to that number to estimate the short squeeze high ...
If this ignorant clown is still short ACHN when 3422 POC results are out, he will fully deserve the financial disaster that's heading his way ... it's well beyond his intellectual capabilities to comprehend why I would buy shares close to the 52 week high ... well, if sticks around, he will find out why ....
Yes, VRUS was acquired by Gilead for $10.8 billion for its nuke (GS-6977 or sofosbuvir) but that was after a Phase 2 trial with Phase 3 in the works.
IDIX was acquired at $3.85 billion after a Phase 1 POC ... ACHN is worth AT LEAST that much after the 3422 Phase 1 POC ... that works out to ~$40 pps ... I don't look at the valuation as a multiple of the present but as a market cap valuation ... add in another $1.2 billion for 2684/ sovaprevir/ 3102 and you get $5 billion or ~$50 pps ... with multiple bidders, who knows where the pps lands up eventually?